Dr. Shelly Bolotin

Scientist

Photo of Dr. Shelly Bolotin
ON WHY PUBLIC HEALTH ONTARIO IS IMPORTANT

"Working at PHO gives me the opportunity to make a direct and meaningful impact on the lives of Ontarians."

Areas of Expertise

  • vaccine-preventable diseases
  • population immunity
  • sero-epidemiology
  • microbiology

Academic Degrees and Accreditations

  • Doctor of Philosophy (Microbiology), University of Toronto
  • Master of Science (Public Health), London School of Hygiene & Tropical Medicine
  • Master of Science (Virology), University of Toronto

PHO Research Interests

  • Epidemiological and microbiological methods to answer questions related to population immunity, in order to identify high-risk groups and predict the future risk for outbreaks or epidemics of vaccine-preventable diseases.
  • Population immunity studies that inform questions related to vaccine effectiveness, waning immunity in certain populations, correlates of population protection of vaccine-preventable diseases and evaluating our current vaccination schedules.

PHO Research Activities

  • A sero-epidemiology program to estimate population immunity to vaccine-preventable diseases, including:
    • A study to determine whether Canada meets the level of population immunity required for measles elimination, identify groups at higher risk of measles outbreaks and predict risk of future outbreaks or epidemics.
    • A study to determine whether Canada’s level of population immunity to varicella (chickenpox) is sufficient to prevent large outbreaks.
    • A study to determine the level of population immunity to mumps, and to assess whether Canada is at risk of future outbreaks due to waning vaccine-mediated immunity
    • A study to investigate the duration of maternal protection from measles in infants in measles elimination settings such as Canada in order to characterize the susceptibility gap between the time at which infants lose maternal antibody protection and vaccination.
    • A study of pertussis immunity to determine immunological differences between infected and uninfected members in the same household.
    • A study to investigate the prevalence in Ontario of Bordetella pertussis strains that are pertactin deficient.

Selected Publications

  1. Guerra FM, Crowcroft NS, Friedman L, Deeks SL, Halperin SA, Severini A, Hatchette TF, Bolotin S; Immunity of Canadians and Risk of Epidemics (iCARE) Network. Waning of measles maternal antibody in infants in measles elimination settings - a systematic literature review. Vaccine. 2018;36(10):1248-55.
  2. Bolotin S, Johnson C, Quach S, Ambrose A, DeCoutere S, Deeks SL, et al; Canadian Immunization Research Network Provincial Collaborative Network. Case-control study of household contacts to examine immunological protection from Bordetella pertussis transmission - study protocol. CMAJ Open. 2017;5(4):E872-7.
  3. Bolotin S, Lim G, Dang V, Crowcroft N, Gubbay J, Mazzulli T, et al. The utility of measles and rubella IgM serology in an elimination setting, Ontario, Canada, 2009-2014. PLoS One. 2017;12(8):e0181172.
  4. Guerra FM, Bolotin S, Lim G, Heffernan J, Deeks SL, Li Y, et al. The basic reproduction number (R0) of measles: a systematic review. Lancet Infect Dis. 2017;17(12):e420-8.
  5. Bolotin S, Deeks SL, Marchand-Austin A, Rilkoff H, Dang V, Walton R, et al. Correlation of real time PCR cycle threshold cut-off with Bordetella pertussis clinical severity. PLoS One. 2015;10(7):e0133209.

View more publications by Dr. Shelly Bolotin on PubMed.gov


Public Health Ontario Scientist Profile: Shelly Bolotin

Dr. Shelly Bolotin discusses what excites her about her work, the impact of her research and why she chose Public Health Ontario.

Duration: 2 min

Chat icon

Contact

media@oahpp.ca

Updated 12 April 2019